Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.

De Caterina R, Salvatore T, Marchioli R.

Data Brief. 2016 Apr 27;7:1541-50. doi: 10.1016/j.dib.2016.04.059. eCollection 2016 Jun.

2.

Cholesterol trials and mortality.

Warren JB, Dimmitt SB, Stampfer HG.

Br J Clin Pharmacol. 2016 Jul;82(1):168-77. doi: 10.1111/bcp.12945. Epub 2016 May 2.

3.
4.

Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis.

Kravchenko J, Berry M, Arbeev K, Lyerly HK, Yashin A, Akushevich I.

Lung Cancer. 2015 Apr;88(1):85-93. doi: 10.1016/j.lungcan.2015.01.006. Epub 2015 Jan 17.

5.

Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.

Nakajima K.

Int J Hepatol. 2012;2012:950693. doi: 10.1155/2012/950693. Epub 2012 Dec 9.

6.

Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention.

Zhou YH, Ye XF, Yu FF, Zhang X, Qin YY, Lu J, He J.

BMC Neurol. 2013 Jan 3;13:1. doi: 10.1186/1471-2377-13-1.

7.

Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials.

Bonovas S, Nikolopoulos GK, Bagos PG.

PLoS One. 2012;7(9):e45259. doi: 10.1371/journal.pone.0045259. Epub 2012 Sep 19. Review.

8.

Treatment of dyslipidemia in the elderly.

Shao H, Chen LQ, Xu J.

J Geriatr Cardiol. 2011 Mar;8(1):55-64. doi: 10.3724/SP.J.1263.2011.00055.

9.

Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Mahdy Ali K, Wonnerth A, Huber K, Wojta J.

Br J Pharmacol. 2012 Nov;167(6):1177-94. doi: 10.1111/j.1476-5381.2012.02081.x. Review.

10.

Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy.

van Bochove K, van Schalkwijk DB, Parnell LD, Lai CQ, Ordovás JM, de Graaf AA, van Ommen B, Arnett DK.

PLoS One. 2012;7(6):e38072. doi: 10.1371/journal.pone.0038072. Epub 2012 Jun 12.

11.

Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.

Tenenbaum A, Medvedofsky D, Fisman EZ, Bubyr L, Matetzky S, Tanne D, Klempfner R, Shemesh J, Goldenberg I.

PLoS One. 2012;7(4):e35298. doi: 10.1371/journal.pone.0035298. Epub 2012 Apr 16.

12.

The clofibrate saga: a retrospective commentary.

Oliver M.

Br J Clin Pharmacol. 2012 Dec;74(6):907-10. doi: 10.1111/j.1365-2125.2012.04282.x. No abstract available.

13.

Mechanistic considerations for human relevance of cancer hazard of di(2-ethylhexyl) phthalate.

Rusyn I, Corton JC.

Mutat Res. 2012 Apr-Jun;750(2):141-58. doi: 10.1016/j.mrrev.2011.12.004. Epub 2011 Dec 20. Review.

14.

The complex interplay between cholesterol and prostate malignancy.

Solomon KR, Freeman MR.

Urol Clin North Am. 2011 Aug;38(3):243-59. doi: 10.1016/j.ucl.2011.04.001. Epub 2011 Jun 22. Review.

15.

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2011 Jun;32(11):1345-61. doi: 10.1093/eurheartj/ehr112. Epub 2011 Apr 29. Review.

16.

Niacin or ezetimibe for patients with, or at risk of coronary heart disease.

Guthrie R.

Clin Med Insights Cardiol. 2010 Oct 31;4:99-110. doi: 10.4137/CMC.S5970.

17.

Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies.

Voulgari C, Papadogiannis D, Tentolouris N.

Vasc Health Risk Manag. 2010 Oct 21;6:883-903. doi: 10.2147/VHRM.S11681. Review.

18.

The periodic health examination.

Sackett DL.

Can Med Assoc J. 1980 Jun 7;122(11):1229. No abstract available.

19.

Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture.

Psaty BM.

Circulation. 2010 Feb 23;121(7):940-5. doi: 10.1161/CIRCULATIONAHA.109.933705. No abstract available.

20.

A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.

Guyton KZ, Chiu WA, Bateson TF, Jinot J, Scott CS, Brown RC, Caldwell JC.

Environ Health Perspect. 2009 Nov;117(11):1664-72. doi: 10.1289/ehp.0900758. Epub 2009 May 15. Review.

Supplemental Content

Support Center